Day 2 :
Mansoura University, Egypt
Salah Aref is currently working as a Professor of Hematology in Mansoura University, Egypt and Director of Mansoura University Oncology Center laboratories. He is also working as a Member in National Board for promotion of professors in hematology. He has published more than 60 papers in the field of hemato-oncology. He has received many awards from Egyptian National Academy of Science, Mansoura University and International Society of Laboratory Hematology. He is acting as an Editorial Board Member and Peer Reviewer of many peer reviewed international journals and authored many books.
Chronic lymphocytic leukemia (CLL) is clonal B cell neoplasm, most frequent in the old age. The clinical course is very heterogenous with the survival time ranging from months to decade. Recently, it was appeared that underlying this heterogeneity are genetic mutation disease progress. In recent years, the development of target therapy necessitates the determination of these generic mutations to tailor the therapy for each patient. In this presentation, we give spotlight on the genetic mutations in CLL and its role in affecting the patient course and treatment.
Ryan S Robetorye has received his MD and PhD degrees from Baylor College of Medicine in Houston, Texas. He is board certified in Clinical Pathology, Hematology and Molecular Genetic Pathology and currently works as a Consultant at the Mayo Clinic in Phoenix, Arizona. He currently serves as the Medical Director of several clinical laboratories at the Mayo Clinic.
Within the past decade, nearly a dozen adult-onset inherited myelodysplastic syndrome (MDS) and leukemia predisposition syndromes have been identified. Individuals with inherited forms of hematologic malignancies are currently underdiagnosed due to the low frequency of cases and low level of clinician awareness of these syndromes. However, these individuals are increasing and likely to be encountered in clinical practice with wider adoption of NGS-based testing for the detection of prognostically significant or targetable genomic alterations in hematologic malignancies. Clinicians must increasingly recognize the possibility that some gene mutations identified in some genes may represent pathogenic germline mutations and initiate appropriate follow-up germline genetic testing. The increasing importance of recognition of germline mutations is evidenced by the inclusion of a new category in the 2016 revision of the WHO classification of myeloid neoplasms and acute leukemia designated classification of myeloid neoplasm with germline predisposition.